From September 1, Bydureon will be available on the Pharmaceutical Benefits Scheme (PBS).
Bydureon, which is the brand name for exenatide, is an injection that is taken once a week to treat type 2 diabetes in conjunction with other oral diabetes medications.
Diabetes Australia CEO Greg Johnson has applauded the move to subsidise Bydureon, saying that it will improve the lives of many people with type 2 diabetes. "This once-a-week injection using an injection pen is a great step forward for many people," says Johnson.
"The injection pen is much easier to use, and has less intrusion on the day-to-day lives of people with diabetes…For many, this once-a-week injection form is ideal, and it’s now affordable with the PBS listing."
For more information about Bydureon, speak with your diabetes educator, GP or endocrinologist and visit pbs.gov.au